The Agenus (AGEN) Receiving Very Positive Press Coverage, Report Finds

The Agenus (AGEN) Receiving Very Positive Press Coverage, Report Finds

Here are some of the headlines that may have impacted AlphaOne’s analysis:

Headlines about Agenus (NASDAQ:AGEN) have been trending very positive recently, according to AlphaOne. AlphaOne, a service of Accern, identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. AlphaOne ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Agenus earned a coverage optimism score of 0.56 on AlphaOne’s scale. AlphaOne also gave media coverage about the biotechnology company an impact score of 94 out of 100, indicating that recent press coverage is extremely likely to have an effect on the stock’s share price in the near future.

Shares of Agenus (NASDAQ:AGEN) opened at 3.50 on Monday. The firm has a 50-day moving average price of $3.58 and a 200-day moving average price of $3.98. Agenus has a 1-year low of $3.20 and a 1-year high of $7.49. The company’s market cap is $346.91 million. Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.14. The firm had revenue of $26.96 million during the quarter, compared to the consensus estimate of $5.22 million. Agenus had a negative return on equity of 359.98% and a negative net margin of 472.80%. On average, equities analysts expect that Agenus will post ($1.27) EPS for the current year.

In other Agenus news, CEO Garo H. Armen purchased 100,000 shares of Agenus stock in a transaction that occurred on Wednesday, April 12th. The stock was purchased at an average price of $3.35 per share, with a total value of $335,000.00. Following the completion of the acquisition, the chief executive officer now owns 1,389,021 shares of the company’s stock, valued at approximately $4,653,220.35. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 7.60% of the company’s stock. About Agenus

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:AGEN”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment